Gritstone Bio’s GRANITE, an individualized neoantigen-targeting immunotherapy, demonstrated potential in treating microsatellite-stable colorectal cancer (MSS-CRC). While the interim Phase 2 data showed positive results, particularly in patients with lower disease burden, the stock price declined due to concerns about the overall impact and future development plans. The company will discuss the progression-free survival data with the FDA and explore potential Phase 2 or 3 trials using ctDNA levels as eligibility criteria.